C
Chemical.AI
Provides a revolutionary research tool to combine AI with Chemistry
About Chemical.AI
Chemical.AI, founded in 2018 by Dr. Ning Xia, is a technology firm that leverages artificial intelligence and automation to innovate the chemical synthesis process. Dr. Xia's journey began as early as 2008 when he developed a demo version of a data-based retrosynthesis concept in France. After returning to China in 2016, he refined the algorithm, leading to the establishment of Chemical.AI. The company is dedicated to improving the efficiency of new drug discovery for pharmaceutical companies by addressing challenges in preclinical chemical synthesis.
The firm operates on a B2B model, providing advanced cheminformatics and automated solutions to over 100 clients in the pharmaceutical, materials, biomedicine, and chemical engineering sectors, including major pharmaceutical companies and contract research organizations (CROs). Its client base spans Asia, Europe, and North America. Revenue is generated through its comprehensive suite of products and services that digitize and accelerate research and development. The company has secured significant financial backing, raising a total of $33.7M through multiple funding rounds, including a Series A led by Sequoia China Seed Fund and a Series B round raising nearly $14 million.
The core of Chemical.AI's offering is its ChemFamily suite, which includes ChemAIRS®, ChemAIOS, and ChemAIoT. ChemAIRS® is an AI-powered platform for designing retrosynthesis routes, capable of generating multiple viable synthetic pathways for a target molecule in minutes by considering factors like reaction feasibility and chiral synthesis strategies. This platform is supplemented by features such as synthesizability assessment and impurity prediction. ChemAIOS is an intelligent lab management system for digitalizing workflows, while ChemAIoT integrates robotics to create automated solutions for the entire experimental process. In 2021, the company launched its Automated Intelligence Laboratory (ChemAILAB®), a high-throughput synthesis facility that combines AI with robotics to enhance synthesis efficiency.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Nov 2022 | $14M | $56M | Junshan Private Equity · Changjiang Innovation Fund Management | ↗ |
Growth signals
Latest recorded traffic for Chemical.AI is 6.9K monthly website visits, down 18.8% over the last three months. Chemical.AI's team grew 9.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Chemical.AI in the Wuhan ecosystem
The Chemical.AI office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- CMChangjiang Innovation Fund Management
- JEJunshan Private Equity
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chemical.AI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chemical.AI’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








